How Are Authorized Representative Responsibilities Allocated for Overseas Registration of Home Medical Devices?

Authorized representative responsibility for overseas registration of home medical devices must be clearly defined before pursuing market authorization. The authorized representative acts as the manufacturer’s legal liaison with the local regulator, handles regulatory communications, maintains the technical file, and supports post-market obligations. However, the manufacturer retains ultimate legal responsibility for the safety and effectiveness of the device. The exact division of duties depends on the target market’s regulatory framework and the product’s risk classification.

Regulatory Scope and Risk Classification

Before engaging an authorized representative, manufacturers must determine whether the product falls within the scope of medical device regulations in the target country (e.g., US FDA, EU MDR, Japan PMDA, China NMPA). The next step is to confirm the risk classification (e.g., Class I/II/III for FDA, or Class A/B/C/D under EU MDR) because this determines the registration pathway and the applicable obligations of the authorized representative. For example, higher-risk devices generally require more extensive technical documentation, clinical evaluation, and post-market oversight, directly impacting the representative’s workload and liability.

Core Responsibilities of the Authorized Representative

In most jurisdictions, the authorized representative is responsible for the following core activities:

• Legal liaison: Acting as the official point of contact between the manufacturer and the local regulatory authority.
• Submission and maintenance of technical files: Preparing, submitting, and updating the registration dossier, including quality system certificates (ISO 13485 or MDSAP), performance verification reports, risk management documentation, and clinical evaluation data.
• Labeling and instructions for use (IFU): Ensuring that product labels and IFUs are adapted to the local language and comply with applicable regulatory requirements.
• Post-market support: Assisting with adverse event reporting, regulatory inspections, change notifications, and renewal processes.

Manufacturer’s Ultimate Responsibility

A common misconception is that the authorized representative assumes all regulatory responsibilities. In reality, the manufacturer retains ultimate accountability for the safety, quality, and efficacy of the device. The authorized representative operates as a local agent; the manufacturer must ensure that the technical file is accurate, the quality system is maintained, and any changes to the device or its application are communicated promptly. Regulators will hold the manufacturer liable for defects or non-compliance, even if the authorized representative failed to perform its duties.

Multi-Country Registration: Reusing Core Documents

For manufacturers planning to register in multiple countries, core technical documents such as risk management files, clinical data, and performance verification reports can be reused. However, each target market requires local adaptation, including translation into the official language, alignment with local standards, and modifications to the authorized representative agreement or local agent arrangement. It is not sufficient to merely translate NMPA or EU documents; the evidence chain must be restructured to meet the target country’s specific format and regulatory expectations.

Key Risks and Mitigation Strategies

Key risks in the authorized representative arrangement include:

• Inadequate capability: An underqualified representative may cause delays by failing to respond correctly to regulator requests or by submitting incomplete documentation.
• Loss of control over certificates: If the agreement does not clearly establish certificate ownership, the manufacturer may lose control over its registration assets.
• Failure to notify changes: If the representative does not promptly communicate regulatory changes, inspections, or requests from the authority, the certificate may lapse or become invalid.

To mitigate these risks, manufacturers should conduct due diligence on the representative’s qualifications and track record, sign a comprehensive agreement that clearly defines responsibilities and liabilities, and establish a robust post-market surveillance process that remains independent of the representative.

Registration Decision Logic

The registration pathway begins with a comprehensive product assessment. Manufacturers must clarify the intended use, mechanism of action, usage environment, contact with the human body, duration of use, sterility, whether the device is powered, whether it includes software or has IVD properties. These factors determine the risk class and the appropriate regulatory pathway. When targeting multiple countries, manufacturers should also identify the applicant entity and the local liability boundary: who holds the certificate, who communicates with the regulator, who handles importation and post-market events, and who triggers change notifications. These elements should be defined in contracts before submission to avoid disputes and market access delays.

Documentation and Evidence Requirements

Typical documentation required for overseas registration includes:

• Product description and model/type matrix
• Intended use and risk classification rationale
• Quality system evidence (ISO 13485 or MDSAP certificate)
• Technical file or design dossier
• Performance verification reports
• Risk management file (e.g., ISO 14971)
• Clinical evaluation or clinical evidence
• Labels and Instructions for Use (IFU) in local language
• Power of attorney or authorization letter
• Existing registration certificates from other markets
• Manufacturer’s declaration and post-market surveillance data

Regulatory authorities focus on consistency across all documents. The claims in the IFU, the models covered by test reports, the scope of clinical evidence, risk management conclusions, label warnings, and information in the registration form must be mutually supportive. Inconsistencies are a leading cause of requests for additional information (deficiencies) and delays.

Common Mistakes

• Treating registration as a simple document submission without properly classifying the product or defining the responsibility matrix.
• Translating NMPA technical files directly without restructuring the evidence for the target market.
• Including too many model variations without ensuring test reports, clinical evidence, or labels cover all of them.
• Selecting a local agent or authorized representative solely based on sales capability, without verifying regulatory competence and contractual clarity.
• Mismatched claims across labels, IFUs, promotional materials, and registration files.
• Failing to plan for multi-country reuse, leading to duplicated effort and higher costs.

Manufacturer’s Pre-Project Checklist

To avoid delays, manufacturers should verify the following before starting an overseas registration:

• Prepare a clear list of target products, model specifications, and intended uses.
• Assess which existing NMPA, CE, FDA, or other market data can be reused.
• Ensure ISO 13485, test reports, risk management documentation, clinical evaluation, and English IFUs are available.
• Define the duties, costs, certificate ownership, and exit mechanisms of the local agent or authorized representative.
• Create a target-country gap analysis table covering required additional testing, translation, notarization, or declarations.

Frequently Asked Questions

Can an authorized representative represent multiple manufacturers?

Yes, an authorized representative can represent multiple manufacturers, provided there is no conflict of interest and the representative has sufficient compliance management capacity. Regulatory authorities may review the representative’s resource allocation and management systems. If a representative takes on too many clients, service quality may suffer. Manufacturers should evaluate the representative’s client load and service record.

What key terms should an authorized representative agreement cover?

The agreement must include the scope of authorization (specific registration activities), certificate ownership (clearly assigned to the manufacturer), responsibilities for changes and renewals, fee structure, confidentiality provisions, termination conditions, and dispute resolution procedures. Significantly, the agreement should require the representative to promptly inform the manufacturer of any regulatory communications, inspection requests, or adverse event reports.

What happens to registration certificates if the authorized representative changes?

Typically, the manufacturer must submit a change application to the regulatory authority and designate a new authorized representative. The outgoing representative is obliged to cooperate in transferring all registration documents. This transition can disrupt product availability, so manufacturers should plan ahead and include a sufficient transition buffer period in the agreement.

Is an authorized representative mandatory for EU registration of home medical devices?

Yes. Under the EU Medical Device Regulation (MDR), any manufacturer located outside the European Economic Area (EEA) must appoint a single authorized representative based in the EEA. The authorized representative is responsible for registration, incident reporting, maintenance of technical documentation, and other regulatory duties. The representative’s identity must appear on the certificate and on the product label.

AIMEILI Regulatory Interpretation and Business Impact

AIMEILI recommends that manufacturers do not treat overseas registration as a one-time document submission, but as a market-entry engineering process. For companies targeting multiple countries, it is essential to first establish a clear set of core technical files and an evidence matrix, then adapt these files for each country. This approach is faster and more reliable than compiling country-specific documentation from scratch. It also supports future changes and renewals.

From a project management perspective, three areas require the earliest attention:

• Product classification and regulatory pathway: A misclassification can cause the entire downstream effort—translation, notarization, authorization, testing, and supplementary documentation—to go in the wrong direction.
• Evidence chain consistency: Ensure that all documents support each other with respect to intended use, performance, safety, and labeling.
• Local partner responsibility boundaries: Clearly define the scope of the local agent’s duties and control over certificates to avoid losing market control in the future.

For project execution, maintain a project ledger that tracks product lists, model types, registration pathways, responsible parties for documentation, translation status, test status, local agent communication, and expected submission dates. This allows early identification of gaps and helps management assess whether the project will meet the launch schedule.

For companies with existing multi-country registrations, build an evidence reuse matrix that distinguishes between core evidence that can be reused across markets and market-specific documents that must be revised or reissued. Keep consistent version control across IFUs, clinical evaluations, risk management files, performance verification reports, and quality system certificates.

Finally, registration is not the end of compliance. Maintain ongoing responsibility for certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label version control, and regulatory updates. AIMEILI recommends that this be included in the annual international registration plan: define market priorities, build a reusable documentation package and gap list, and schedule submissions, deficiency responses, post-market surveillance, and renewals. This approach builds repeatable regulatory competence and reduces the cost of entering new markets.